Dear Editor,

Acute lymphoblastic leukemia (ALL) is the most common type of cancer in children, representing approximately one-third of pediatric cancers. Febrile neutropenia (FN) is the most common and potentially lethal complication in patients undergoing chemotherapy \[[@CR1]\]. About half of the children treated with chemotherapy for cancer develop at least one FN episode \[[@CR2]\]. The world is currently facing a pandemic caused by a new coronavirus \[[@CR3]\] and although SARS-CoV-2 infection appears to be less aggressive in children \[[@CR4]\], however, the evolution of COVID-19 in children with cancer is still uncertain. Here, we describe three cases of patients with ALL who presented with FN and COVID-19.

Two patients admitted to the emergency department with a history of ALL and fever (Table [1](#Tab1){ref-type="table"}), the initial complete blood count showed neutropenia (\< 500 neutrophils per mm^3^). Another hospitalized patient presented fever without initial neutropenia (patient 2), however, he developed neutropenia in subsequent days. Patients 1 and 2 were on consolidation therapy for ALL, and they had received chemotherapy drugs in the last 14 days. Patient 3 received daily immunosuppression due to hematopoietic stem cell transplantation.Table 1Characteristics of children with febrile neutropenia and acute lymphoblastic leukemia infected with SARS-CoV-2Reference rangePatient 1Patient 2Patient 3Age (years)948SexFemFemFemMedical history  ConditionsALL in consolidation therapyALL in consolidation therapyALL post-hematopoietic stem cells transplantation  MedicamentsCytarabine and cyclophosphamideMethotrexate and mercaptopurineMycophenolate, prednisoneValues on admission  White cell count (per mm^3^)10009201300  Neutrophils (per mm^3^)150350475  Lymphocytes (per mm^3^)510370110  Platelets (per mm^3^)295,000353,0005000  Hemoglobin (gr/dL)8.711.78.4  Prothrombin time (second)1711.411.2  Activated thromboplastin time (second)2626.827.2  Fibrinogen (mg/dL)199--400332473406  D-dimer -ng/ml100--56080017001200  Antithrombin III (U/mL)0.90--1.300.981.250.99  Lactic dehydrogenase110--295717482301  Interleukin (6 pg/mL)0--5.941\--  Ferritin (ng/mL)7--140209223662190  Procalcitonin (ng/mL)\< 0.50.270.050.17  C-reactive protein (mg/L)1.3500.4110  AntibioticsClarithromycinClarithromycinClarithromycin  ThromboprophylaxisEnoxaparinEnoxaparinNo  SurvivedYesYesNo  Days of hospital stay14131

Patients developed respiratory symptoms after the initial fever, one progressing to respiratory distress (patient 3), admitted to the intensive care unit. None of the patients presented gastrointestinal symptoms. The patients had a positive PCR test for SARS-CoV-2. In addition, a simple chest computed tomography was performed, with typical COVID-19 appearance in patients 1 and 3.

No other site of infection was found in our patients, the procalcitonin value did not suggest bacterial infection, and no microorganism was identified on blood cultures. Patients 1 and 2 had a hospital stay of 2 weeks; they remained hospitalized because of the uncertainty regarding their clinical evolution due to the lack of medical reports of COVID-19 in patients with ALL and FN. Patient 3 required invasive mechanical ventilation, furthermore, she deteriorated hemodynamically and presented cardiac arrest that did not respond to cardiopulmonary resuscitation.

Patients 1 and 2 were treated with enoxaparin, even though they did not meet criteria for disseminated intravascular coagulation. This treatment was given due to the multiple alterations in coagulation associated with worse prognosis that have been described in patients with COVID-19 \[[@CR5], [@CR6]\]. Our patients presented elevation of D-dimer, which is suggestive of thrombotic activity and severe inflammatory process. Patient 3 did not receive thromboprophylaxis due to severe thrombocytopenia.

We present this first experience in Mexican children with FN and ALL. COVID-19 should be suspected in children with FN even in the absence of other symptoms. The prognosis of these patients remains uncertain and larger series reporting the course of SARS-CoV-2 infection in children with hemato-oncological diseases are needed to develop specific clinical guidelines.
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